Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina
| Autor: | Nicolás Kreplak, Patricia Campos, Lupe Marín, Santiago Olszevicki, Soledad González, Elisa Estenssoro, Martin R Salazar, Marina Pifano, Enio Garcia, Leticia Ceriani, Franco Marsico, Ana Calabria, Lorena Regairaz, Veronica V. González Martínez, Teresa Varela |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
2019-20 coronavirus outbreak Medicine (General) Research paper Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectious diseases R5-920 Internal medicine Medicine Cumulative incidence In patient Ciencias Médicas y de la Salud Cnfectious diseases business.industry Vaccination Retrospective cohort study General Medicine vaccination Immunization covid-19 Ciencias Médicas Infectious diseases business Covid-19 |
| Zdroj: | EClinicalMedicine, Vol 40, Iss, Pp 101126-(2021) SEDICI (UNLP) Universidad Nacional de La Plata instacron:UNLP CIC Digital (CICBA) Comisión de Investigaciones Científicas de la Provincia de Buenos Aires instacron:CICBA EClinicalMedicine |
| ISSN: | 2589-5370 |
| Popis: | Background A first-dose of various vaccines provides acceptable protection against infections by SARS-CoV-2 and evolution to the most severe forms of COVID-19. The recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), was proven efficacious but information about effectiveness in the real-world setting is lacking. The aim of our study was to investigate the association between the rollout of the first component (rAd26) of Gam-COVID-Vac and PCR-positive tests, hospitalisations and deaths. Methods We conducted a retrospective cohort study which analyzed individuals aged 60-79 who self-registered in the online vaccination system of the Province of Buenos Aires, Argentina, from December 29, 2020 to March 21, 2021. Exclusion criteria were having a previous positive RT-PCR or antigen tests for SARS-CoV-2, having received other vaccines, or two doses of any vaccine. Proportions of new laboratory-confirmed SARS-CoV-2 infections, hospitalisations and deaths until 83 days of vaccination were compared between vaccinated and unvaccinated subjects. Vaccine effectiveness for the three outcomes was calculated as (1–OR) × 100. Kaplan-Meier cumulative incidence curves were constructed. Findings During the study period 415995 registered subjects received the first component of Gam-COVID-Vac; 40387 belonged to the 60-79 age group, and were compared to 38978 unvaccinated. Vaccine effectiveness for preventing laboratory-confirmed infections was 78•6% [CI95% 74·8 - 81·7]; and for reducing hospitalizations and deaths was, respectively, 87·6% [CI95% 80·3 - 92·2] and 84·8% [CI95% 75·0 - 90·7]. Effectiveness was high across all subgroups. Interpretation Similarly to other vaccines, the administration of one dose of Gam-COVID-Vac was effective for a wide range of COVID-19–related outcomes. Facultad de Ciencias Médicas |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|